Cara Therapeutics Inc Share Price (NASDAQ: CARA)

▲

-15.96

(-100%)

Last updated on April 14, 2025 at 12:00 am IST

$₹

The stock has been delisted from the stock exchange on 14 Apr 2025

Check the interactive Cara Therapeutics Inc Stock chart to analyse performance

Cara Therapeutics Inc Key Stats

Check Cara Therapeutics Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$15.96
Open	$5.39
Market Capitalization	$25.4M
Today's Volume	$237.1K
Revenue TTM	$7.1M
EBITDA	$-55.6M
Earnings Per Share (EPS)	$-15.53
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-270.01%

Global Institutional Holdings in Cara Therapeutics Inc

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
0.31%
Rockefeller Capital Management L.P.
0.28%
Farallon Capital Management, L.L.C.
0.24%
Susquehanna International Group, LLP
0.21%
Renaissance Technologies Corp
0.17%
Shay Capital LLC
0.16%

Analyst Recommendation on Cara Therapeutics Inc Stock

Rating

Trend

Buy

81%Buy

18%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Cara Therapeutics Inc(by analysts ranked 0 to 5 stars)

Cara Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$19.9M	↑ 47.64%
Net Income	$-106.4M	↑ 43.72%
Net Profit Margin	-534.91%	↑ 14.6%

	FY20	Y/Y Change
Revenue	$135.1M	↑ 579.28%
Net Income	$8.4M	↓ 107.91%
Net Profit Margin	6.23%	↑ 541.14%

	FY21	Y/Y Change
Revenue	$23.0M	↓ 82.95%
Net Income	$-88.2M	↓ 1148.67%
Net Profit Margin	-382.98%	↓ 389.21%

	FY22	Y/Y Change
Revenue	$41.9M	↑ 81.81%
Net Income	$-83.4M	↓ 5.42%
Net Profit Margin	-199.23%	↑ 183.75%

	FY23	Y/Y Change
Revenue	$21.0M	↓ 49.92%
Net Income	$-118.5M	↑ 42.08%
Net Profit Margin	-565.21%	↓ 365.98%

	FY24	Y/Y Change
Revenue	$7.1M	↓ 65.96%
Net Income	$-70.9M	↓ 40.2%
Net Profit Margin	-992.95%	↓ 427.74%

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

	Q3 FY23	Q/Q Change
Revenue	$4.9M	↓ 29.81%
Net Income	$-28.0M	↓ 10.95%
Net Profit Margin	-576.08%	↓ 122.03%

	Q4 FY23	Q/Q Change
Revenue	$3.0M	↓ 38.27%
Net Income	$-32.3M	↑ 15.36%
Net Profit Margin	-1.1K%	↓ 500.38%

	Q1 FY24	Q/Q Change
Revenue	$2.1M	↓ 28.93%
Net Income	$-30.7M	↓ 5.07%
Net Profit Margin	-1.4K%	↓ 361.29%

	Q2 FY24	Q/Q Change
Revenue	$991.0K	↓ 53.58%
Net Income	$-20.0M	↓ 34.79%
Net Profit Margin	-2.0K%	↓ 582.03%

	Q3 FY24	Q/Q Change
Revenue	$2.6M	↑ 157.92%
Net Income	$-12.5M	↓ 37.67%
Net Profit Margin	-488.11%	↑ 1531.67%

	Q4 FY24	Q/Q Change
Revenue	$1.5M	↓ 43.08%
Net Income	$-7.7M	↓ 38.45%
Net Profit Margin	-527.77%	↓ 39.66%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$19.9M	↑ 47.64%

	FY20	Y/Y Change
Profit	$28.0M	↑ 40.86%

	FY21	Y/Y Change
Profit	$23.0M	↓ 17.79%

	FY22	Y/Y Change
Profit	$34.6M	↑ 50.26%

	FY23	Y/Y Change
Profit	$14.8M	↓ 57.24%

	FY24	Y/Y Change
Profit	$7.1M	↓ 51.76%

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

	Q3 FY23	Q/Q Change
Profit	$3.3M	↓ 40.02%

	Q4 FY23	Q/Q Change
Profit	$2.3M	↓ 30.05%

	Q1 FY24	Q/Q Change
Profit	$1.5M	↓ 36.34%

	Q2 FY24	Q/Q Change
Profit	$991.0K	↓ 32.72%

	Q3 FY24	Q/Q Change
Profit	$2.6M	↑ 157.92%

	Q4 FY24	Q/Q Change
Profit	$1.5M	↓ 43.08%

FY19

FY20

FY21

FY22

	FY19	Y/Y Change
Operating Cash Flow	$-109.2M	↑ 389.78%
Investing Cash Flow	$-30.5M	↓ 63.15%
Financing Cash Flow	$142.6M	↑ 28.69%

	FY20	Y/Y Change
Operating Cash Flow	$-5.5M	↓ 94.98%
Investing Cash Flow	$-20.3M	↓ 33.56%
Financing Cash Flow	$39.1M	↓ 72.55%

	FY21	Y/Y Change
Operating Cash Flow	$-60.1M	↑ 995.08%
Investing Cash Flow	$-4.8M	↓ 76.57%
Financing Cash Flow	$46.6M	↑ 19.08%

	FY22	Y/Y Change
Operating Cash Flow	$-78.7M	↑ 31.03%
Investing Cash Flow	$128.7M	↓ 2809.05%
Financing Cash Flow	$311.0K	↓ 99.33%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-19.6M	↓ 3.91%
Investing Cash Flow	$23.2M	↓ 29.41%
Financing Cash Flow	$1.1M	↑ 0.0%

About Cara Therapeutics Inc

Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Organization	Cara Therapeutics Inc
Employees	10
CEO	Mr. Christopher A. Posner
Industry	Health Technology

Key Management of Cara Therapeutics Inc

Name	Title
Mr. Christopher A. Posner	President, CEO & Director
Mr. Ryan D. Maynard	Chief Financial Officer
Mr. Scott M. Terrillion J.D.	Chief Compliance Officer, General Counsel & Corporate Secretary
Mr. Matthew Murphy	Manager of Investor Relations

Important FAQs about investing in CARA Stock from India :

What is Cara Therapeutics Inc share price today?

Cara Therapeutics Inc share price today is as on April 14, 2025 at 12:00 am IST at the close of the market. Cara Therapeutics Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Cara Therapeutics Inc share?

Cara Therapeutics Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Cara Therapeutics Inc stock price today i.e. April 14, 2025 at 12:00 am IST is closed at , lower by 100% versus the 52 week high.

How to invest in Cara Therapeutics Inc Stock (CARA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cara Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cara Therapeutics Inc Shares .

What is the minimum amount required to buy Cara Therapeutics Inc Stock (CARA) from India?

Indian investors can start investing in Cara Therapeutics Inc (CARA) shares with as little as ₹87.823 or $1 (as of September 17, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹878.23 in Cara Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 17, 2025). Learn more about fractional shares .

What are the returns that Cara Therapeutics Inc has given to Indian investors in the last 5 years?

Cara Therapeutics Inc stock has given 0.0% share price returns and 19.41% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

Atara Biotherapeutics Inc
$11.66
-2.35%
Usana Health Sciences Inc.
$30.58
+2.24%
At&t, Inc.
$29.34
-0.95%
Clear Channel Outdoor Holdings Inc.
$1.29
-3.73%
Cemex, S.a.b. De C.v.
$9.56
+0.21%
Epsium Enterprise Limited
$41.30
+6.66%
Sadot Group Inc
$7.77
-5.82%
Deswell Industries Inc
$3.80
-5.47%
Cohen & Steers Tax-advantage
$20.69
-0.29%

Explore all